Weight loss and type 2 diabetes jabs 'could benefit people with alcohol abuse problems'

17 October 2024, 09:51

The study found that the drugs "should be investigated as a novel pharmacotherapy treatment option" for people with alcohol and opioid addiction
The study found that the drugs "should be investigated as a novel pharmacotherapy treatment option" for people with alcohol and opioid addiction. Picture: Alamy

By Asher McShane

Weight loss and type 2 diabetes jabs could benefit people with alcohol abuse problems, according to a new study.

Listen to this article

Loading audio...

Researchers found the common drugs led to a 50% lower rate of alcohol intoxication in people taking them compared to people not prescribed them.

Their study, published in the journal Addiction, also found that off-label use of the drugs could also help people addicted to opioids.

The researchers looked at glucose-dependent insulinotropic polypeptide (GIP) drugs, which they said include brand name Mounjaro, and/or glucagon-like peptide-1 receptor agonists (GLP-1 RA), which they said included the drug Ozempic.

Health experts have suggested these drugs may curb addictions because they work on appetite but also parts of the brain which help maintain addictive behaviour.

For the new study, led by Loyola University Chicago in the US, experts looked at 503,747 people with a history of opioid use disorder, of which 8,103 had a prescription for a GLP-1 RA or GIP.

The study found that people with the disorder who had a GLP-1 RA or GIP prescription had a 40% lower rate of opioid overdose compared with those who did not have a prescription.

The study also looked at 817,309 people with a history of alcohol use disorder, of which 5,621 had a prescription for a GLP-1 RA or GIP.

It found that people with alcohol use disorder who had a GLP-1 RA or GIP prescription had a 50% lower rate of alcohol intoxication compared with those who did not have a prescription.

The authors said their results showed that the drugs "should be investigated as a novel pharmacotherapy treatment option" for people with alcohol and opioid addiction.